Zobrazeno 81 - 90
of 1 635
pro vyhledávání: ''
Autor:
Kim Wai Yu, Laura Kruper, Yuan Yuan, Joanne E. Mortimer, Daphne Stewart, Louise Wong, Jae Jung, Samuel Chung, Sanjeet Dadwal, Jill Cooper
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem. Patients Treating physicians a
Autor:
Jennifer Caplain, Madhumita Das, Elizabeth Grimm, Shrikar Rajagopal, Oksana B. Serebrennikova, Robert E. Martell, Philip N. Tsichlis, Mohammad Wasif Saif
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1323-1331
Metformin activates AMP-related pathways leading to inactivation of mammalian target of rapamycin (mTOR) and suppression of its downstream effectors, crucial for cancer growth. Epidemiologic studies showed a reduced incidence and improved survival in
Autor:
Takanori Matsui, Tetsuo Touyama, Junichi Hasegawa, Keiji Inoue, Yoshinori Munemoto, Atsushi Ohtsu, Kiyoshi Ishigure, Takayuki Yoshino, Hiroshi Ishikawa, Yutaka Ogata, Koji Oba, Hideyuki Ishida, Dai Manaka, Yoshihiko Maehara, Koichi Goto, Junichi Sakamoto, Akinori Takagane, Masahito Kotaka, K. Shinozaki
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Adjuvant FOLFOX therapy is an established standard-of-care for resected colon cancer. Peripheral sensory neuropathy (PSN) is regarded as the major toxicity issue related to FOLFOX therapy. There have been a few reports on the recovery status
Autor:
Hongkun Wang, Jimmy J. Hwang, John F. Deeken, Michael J. Pishvaian, Emanuel F. Petricoin, Brandon G. Smaglo, Paula R. Pohlmann, John L. Marshall, Aiwu R. He, Filipa Lynce, Deepa S. Subramaniam
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS: Patient
Autor:
Tetsuya Oguri, Kazuki Sone, Akio Niimi, Osamu Takakuwa, Yoshihiro Kanemitsu, Takehiro Uemura, Satoshi Fukuda, Yutaka Ito, Hirotsugu Ohkubo, Akira Takeuchi, Masaya Takemura, Ken Maeno, Eiji Kunii
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1229-1239
Purpose ABCC11/MRP8 (ABCC11) is an ATP-binding cassette transporter that is involved in regulating cellular sensitivity and resistance for many anti-cancer drugs. Since 5-fluorouracil (5-FU) is one of the substrates for ABCC11, we examined whether AB
Autor:
Stefania Crucitta, Giulia Gianfilippo, Andrea Fontana, Lorenzo Fontanelli, Giuliana Restante, Marzia Del Re, Matteo Ghilli, Eleonora Rofi, Stefano Fogli, Romano Danesi, I. Stasi, E. Bona, I. Bertolini
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1219-1227
To investigate the association between single nucleotide polymorphisms (SNPs) in endothelial nitric oxide synthase (eNOS) and interleukin-8 (IL-8) genes and risk of developing bevacizumab-related adverse events in metastatic breast cancer (mBC) patie
Autor:
Heinz Joseph Lenz, Thehang Luu, Edward M. Newman, Mihaela C. Cristea, Dean Lim, Paul Frankel, Leonard Joseph Appleman, David R. Gandara, Richard Piekarz, Brian F. Kiesel, Jan H. Beumer
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: The reported maximum tolerated dose (MTD) of single agent belinostat is 1000 mg/m(2) given days 1-5, every 21 days. Pre-clinical evidence suggests histone deacetylase inhibitors enhance retinoic acid signaling in a variety of solid tumors. W
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1115-1123
The aim of this study was to evaluate the safety and efficacy of combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Patients with clinically resectable, locally advanced esophageal cancer
Autor:
Tatsunori Shimoi, Shinsuke Sasada, Kenta Takahashi, Yae Takehara, Kenji Tamura, Mayu Yunokawa, Kan Yonemori, Mitsuya Ishikawa, Tomoyasu Kato
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1051-1058
Current strategies for the treatment of endometrial cancer in older adult patients require re-evaluation given the global trend in population aging, especially in Japan. We sought to evaluate initial treatment offered to older adult patients with end
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: To characterize the effects of disease type and clinical characteristics on the pharmacokinetics of siltuximab, an IL-6 inhibiting monoclonal antibody. METHODS: Siltuximab pharmacokinetic data were combined from 7 phase I/II clinical trials.